150 related articles for article (PubMed ID: 25938482)
1. Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.
Yousif AM; Minopoli M; Bifulco K; Ingangi V; Di Carluccio G; Merlino F; Motti ML; Grieco P; Carriero MV
PLoS One; 2015; 10(5):e0126172. PubMed ID: 25938482
[TBL] [Abstract][Full Text] [Related]
2. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.
Yousif AM; Ingangi V; Merlino F; Brancaccio D; Minopoli M; Bellavita R; Novellino E; Carriero MV; Carotenuto A; Grieco P
Eur J Med Chem; 2018 Jan; 143():348-360. PubMed ID: 29202399
[TBL] [Abstract][Full Text] [Related]
4. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.
Bifulco K; Longanesi-Cattani I; Gargiulo L; Maglio O; Cataldi M; De Rosa M; Stoppelli MP; Pavone V; Carriero MV
FEBS Lett; 2008 Apr; 582(7):1141-6. PubMed ID: 18339322
[TBL] [Abstract][Full Text] [Related]
5. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.
Genua M; Ingangi V; Fonteyne P; Piontini A; Yousif AM; Merlino F; Grieco P; Malesci A; Carriero MV; Danese S
Inflamm Bowel Dis; 2016 Oct; 22(10):2390-401. PubMed ID: 27537052
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Carriero MV; Longanesi-Cattani I; Bifulco K; Maglio O; Lista L; Barbieri A; Votta G; Masucci MT; Arra C; Franco R; De Rosa M; Stoppelli MP; Pavone V
Mol Cancer Ther; 2009 Sep; 8(9):2708-17. PubMed ID: 19706734
[TBL] [Abstract][Full Text] [Related]
9. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
10. The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.
Bifulco K; Longanesi-Cattani I; Gala M; DI Carluccio G; Masucci MT; Pavone V; Lista L; Arra C; Stoppelli MP; Carriero MV
J Thromb Haemost; 2010 Dec; 8(12):2789-99. PubMed ID: 20880257
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
12. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
[TBL] [Abstract][Full Text] [Related]
13. A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting.
Bifulco K; Longanesi-Cattani I; Liguori E; Arra C; Rea D; Masucci MT; De Rosa M; Pavone V; Stoppelli MP; Carriero MV
Mol Cancer Ther; 2013 Oct; 12(10):1981-93. PubMed ID: 23939376
[TBL] [Abstract][Full Text] [Related]
14. Sesamin inhibits bacterial formylpeptide-induced inflammatory responses in a murine air-pouch model and in THP-1 human monocytes.
Cui Y; Hou X; Chen J; Xie L; Yang L; Le Y
J Nutr; 2010 Feb; 140(2):377-81. PubMed ID: 20032476
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
[TBL] [Abstract][Full Text] [Related]
16. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
Pliyev BK; Antonova OA; Menshikov M
Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
[TBL] [Abstract][Full Text] [Related]
17.
Napolitano F; Rossi FW; Pesapane A; Varricchio S; Ilardi G; Mascolo M; Staibano S; Lavecchia A; Ragno P; Selleri C; Marone G; Matucci-Cerinic M; de Paulis A; Montuori N
Front Immunol; 2018; 9():574. PubMed ID: 29670612
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages.
Gemperle C; Schmid M; Herova M; Marti-Jaun J; Wuest SJ; Loretz C; Hersberger M
PLoS One; 2012; 7(11):e50195. PubMed ID: 23185575
[TBL] [Abstract][Full Text] [Related]
19. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
[TBL] [Abstract][Full Text] [Related]
20. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.
Carriero MV; Bifulco K; Minopoli M; Lista L; Maglio O; Mele L; Di Carluccio G; De Rosa M; Pavone V
Mol Cancer Ther; 2014 May; 13(5):1092-104. PubMed ID: 24705350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
